These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27281624)

  • 1. Women at a Disadvantage in Fluorouracil Treatment.
    Ciccolini J; Milano G
    JAMA Oncol; 2016 Jun; 2(6):829-30. PubMed ID: 27281624
    [No Abstract]   [Full Text] [Related]  

  • 2. Women at a Disadvantage in Fluorouracil Treatment-Reply.
    Boige V; Vincent M; Laurent-Puig P
    JAMA Oncol; 2016 Jun; 2(6):830-1. PubMed ID: 27281626
    [No Abstract]   [Full Text] [Related]  

  • 3. DPYD variants to predict 5-FU toxicity: the ultimate proof.
    Innocenti F
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381394
    [No Abstract]   [Full Text] [Related]  

  • 4. 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798).
    González-Perera I; Gutiérrez-Nicolás F; Nazco-Casariego GJ; Ramos-Díaz R; Hernández-San Gil R; Pérez-Pérez JA; González García J; González De La Fuente GA
    J Oncol Pharm Pract; 2017 Jul; 23(5):396-398. PubMed ID: 27122156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
    Schneider HB; Becker H
    Eur J Med Res; 2003 May; 8(5):226-8. PubMed ID: 12844478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma].
    Zhang H; Li YM; Yu CH; Wang SQ; Ji F; Chen CX
    Zhonghua Nei Ke Za Zhi; 2007 Feb; 46(2):103-6. PubMed ID: 17445431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5-fluorouracil therapy.
    Altundag O; Altundag K; Silay K; Turen S
    Med Hypotheses; 2005; 65(6):1196. PubMed ID: 15951130
    [No Abstract]   [Full Text] [Related]  

  • 8. Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?
    Deenen MJ; Beijnen JH; Schellens JH
    J Clin Oncol; 2008 Oct; 26(30):4997-8; author reply 4998-9. PubMed ID: 18809598
    [No Abstract]   [Full Text] [Related]  

  • 9. 5FU and oxaliplatin-containing chemotherapy in two dihydropyrimidine dehydrogenase-deficient patients.
    Reerink O; Mulder NH; Szabo BG; Hospers GA
    Anticancer Res; 2004; 24(3b):1969-71. PubMed ID: 15274386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of oral fluoropyrimidines in colon cancer: their role and new directions.
    Benson AB
    J Natl Compr Canc Netw; 2003 Oct; 1 Suppl 3():S-17-21. PubMed ID: 23570133
    [No Abstract]   [Full Text] [Related]  

  • 11. MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD.
    Chai J; Dong W; Xie C; Wang L; Han DL; Wang S; Guo HL; Zhang ZL
    IUBMB Life; 2015 Mar; 67(3):191-201. PubMed ID: 25873402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Severe capecitabine-associated toxicity in a patient carrying a mutation in the dihydropyrimidine dehydrogenase gen].
    González-Haba E
    Farm Hosp; 2012; 36(6):554-5. PubMed ID: 23461455
    [No Abstract]   [Full Text] [Related]  

  • 13. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
    Mauritz R; van Groeningen CJ; Smid K; Jansen G; Pinedo HM; Peters GJ
    Int J Cancer; 2007 Jun; 120(12):2609-12. PubMed ID: 17330233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of target gene polymorphisms in 5-Fluorouracil toxicity: a case report.
    Scalvini A; Ferrari V; Bodei S; Arcangeli G; Consoli F; Spano P; Sigala S
    Pharmacology; 2012; 89(1-2):99-102. PubMed ID: 22343422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fatal drug-drug interaction between 5-fluorouracil and brivudine].
    García Fernández V; Garrido Arévalo M; Labrada González E; Hidalgo Correas FJ
    Farm Hosp; 2013; 37(1):72-3. PubMed ID: 23461503
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
    Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
    Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
    Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?
    Mercier C; Ciccolini J
    Trends Pharmacol Sci; 2007 Dec; 28(12):597-8. PubMed ID: 18001850
    [No Abstract]   [Full Text] [Related]  

  • 19. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
    Ostapowicz A; Dołegowska B
    Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.